The Acquirer: A large-cap pharma company ($80B+ market cap) with an aging oncology franchise facing a patent cliff in 2028–2029. The company needs to replenish its pipeline through external innovation.
The Target — Veridian Oncology: A mid-cap biotech with a lead asset in Phase III for second-line non-small cell lung cancer (NSCLC). The drug is a novel immune cell trafficking modulator delivered via IV infusion. Veridian is seeking $12B, representing a 40–60% premium to its current trading price.
The Question: Does the deal work? Management's model assumes 30% peak market share at $180K net price per patient per year, reaching peak sales in 5 years. The acquirer's BD team wants to pressure-test these commercial assumptions before committing $12B.
The Method: 958 digital twins — synthetic personas built from real consumer behavioural data representing potential patients and general population — were asked 21 questions across five domains: price sensitivity, switching willingness, treatment convenience, side effect tolerance, and competitive preference.
The Purpose: To stress-test the three commercial assumptions that drive the deal's rNPV — peak market share, net price per patient, and time to peak sales. These are the inputs that determine whether the $12B asking price is justified.
| Model Input | Mgmt Assumption | Twin Questions That Test It | # Questions |
|---|---|---|---|
| Peak market share | 30% | Switching willingness, brand preference, adoption timing, accelerated approval sentiment | 7 |
| Net price / patient / year | $180K | Van Westendorp pricing (too cheap, good value, expensive, too expensive), household savings, cost vs. side effect trade-off | 6 |
| Years to peak sales | 5 | Treatment format preference, travel willingness, clinic visit impact, daily routine importance | 4 |
| Competitive positioning | — | Deciding factor between drugs, side effect tolerance, dealbreaker side effects, discontinuation timing | 4 |
Accelerated approval is a negative, not a positive. 84% of twins say faster approval with less long-term data makes them less willing to try a drug (mean 1.91/5). If Veridian pursues an accelerated pathway, it will actively suppress adoption.
The acceptable OOP price ceiling is $250–500/month. 91% consider $100/month or below "good value." While this is out-of-pocket (not wholesale), it signals formulary pushback and co-pay assistance dependency that compresses net price below management's $180K assumption.
Format mismatch is the silent deal-killer. Most oncology biologics are IV infusions. 88% of twins prefer a daily pill. This isn't a deal-breaker on its own, but combined with low switching willingness and brand conservatism, it extends the uptake ramp from 5 to 7 years.
If Veridian's drug avoids cognitive fog, market share has upside. Side effects are 24x more important than price as a deciding factor. Due diligence should prioritize Veridian's Phase III safety data, specifically cognitive and neurological adverse events. A clean profile here could push peak share above 18%.
Mean switching willingness is 2.2/5. 73% rated 1 or 2 (unlikely/very unlikely). 82% prefer an established brand over a newer option with identical results. Management's 30% peak share assumption requires adoption behaviour the patient data flatly contradicts. Twin-adjusted share: 18%.
53% won't try a new drug until their doctor recommends it. Another 33% want 2+ years on market. Only 6.5% would try immediately. Combined with the 88% preference for oral treatment (Veridian's drug is likely an infusion), the ramp to peak is 7 years, not 5.
84% of twins say faster approval with less long-term data makes them less willing to try a drug (mean 1.91/5). If Veridian pursues an accelerated regulatory pathway, it will suppress — not accelerate — patient adoption. This is counter-intuitive and directly challenges a common bull-case assumption.
62% say fewer side effects is the deciding factor between two similar drugs. Price registers at just 3%. If Veridian's Phase III safety data shows a cleaner profile than the incumbent — particularly on cognitive fog (the #1 dealbreaker at 63%) — market share has meaningful upside beyond the 18% base case.
63% of twins cite cognitive fog as the side effect most likely to make them stop treatment. 56% would switch immediately if any side effects appear in month 1. Due diligence should request a detailed breakdown of Veridian's neurological AE profile from clinical trials. This single data point could swing the valuation.
53% of twins won't try a new treatment until their doctor recommends it. Doctor influence scores 3.73/5. The #2 reason to switch treatments is "doctor's recommendation" (35%). KOL strategy and medical affairs investment will drive adoption more than any DTC or patient marketing spend.